Just last Friday, JPMorgan had upgraded Torrent Pharma to an “Overweight” rating with a price target of ₹3,800 from ₹2,100 earlier, driven by multiple factors. You can read more on that here.
Just last Friday, JPMorgan had upgraded Torrent Pharma to an “Overweight” rating with a price target of ₹3,800 from ₹2,100 earlier, driven by multiple factors. You can read more on that here.